检索结果-南通市图书馆

世界核心医学期刊文摘（心脏病学分册） 2007年第10期3卷 38-页

作者： Jahangir A. Lee V. Friedman P.A. 杜媛 Division of Cardiovascular diseases Mayo Clinic200 First St SWRochesterMN 55905United States Dr.

背景:孤立性房颤的长期自然病程尚不清楚。作者拟确定经30年由阵发性房颤进展为永久性房颤的发生率及预测因素,同时比较房颤患者与对照个体发生心力衰竭、血栓栓塞和死亡的长期风险。

关键词：房颤阵发性永久性心房纤颤孤立性患者

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

移植前终末器官疾病对移植受者发生皮肤肿瘤的影响

引用

世界核心医学期刊文摘（皮肤病学分册） 2006年第2期2卷 7-7页

作者： Otley C.C. Cherikh W.S. Salasche S.J. 焦婷 Division of Dermatologic Surgery Mayo Clinic 200 First St SW Rochester MN 55905 United StatesDr.

Background: Solid organ transplant recipients are at increased risk for posttransplant neoplasms. Objective: Our purpose was to determine whether various diseases causing end- organ failure are associated with different degrees of risk of skin cancer development after transplantation. Methods: The Organ Procurement and Transplantation Network/United Network for Organ Sharing Transplant Tumor Registry was searched for the incidence of skin cancer among kidney, liver, and heart transplant recipients in the United States between 1996 and 2001. Multivariate analysis was used to determine the association between disease diagnosis and posttransplant skin cancer. Results: Transplant recipients with specific pretransplant diseases, such as polycystic kidney disease and cholestatic liver disease, were at increased risk for skin cancer. Patients with diabetesmellitus had a lower incidence of skin cancer after kidney transplantation. Limitations: The study had only a brief follow- up period, indirect assessment of photodamage, and possible underreporting. Conclusion: Transplant recipients with a history of certain diseases warrant intensive skin cancer surveillance and strict sun- protective practices.

关键词：皮肤肿瘤移植受者疾病诊断移植肿瘤间接评估防护措施多囊肾多变量分析前有

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

右心室在心脏手术围手术期的展望：Ⅰ．解剖、生理及功能评估

引用

麻醉与镇痛 2011年第2期7卷 1-16页

作者： Frangois Haddad, MD Pierre Couture, MD Claude Tousignant, MD Andre Y. Denault, MD 曾真(译) 杜冬萍(校) Department of Anesthesiology Montreal Heart Institute and Universite de Montreal Montreal Quebec Canada Division of Cardiovascular Medicine Stanford University Stanford California Department of Anesthesia St. Michael's Hospital University of Toronto Toronto Ontario Canada 不详

近些年，在心血管疾病和心脏手术中，右心室功能的重要性已被认识到。右心功能障碍是心衰、先天性心脏病、血管疾病和心脏手术预后不良的显著预测因子。两篇文章的第1篇中，我们将回顾右心室解剖、生理以及对右心室的评估。此文中，重... 详细信息

近些年，在心血管疾病和心脏手术中，右心室功能的重要性已被认识到。右心功能障碍是心衰、先天性心脏病、血管疾病和心脏手术预后不良的显著预测因子。两篇文章的第1篇中，我们将回顾右心室解剖、生理以及对右心室的评估。此文中，重点围绕通过心动超声评估右心室结构和功能。第2篇主要讨论病理生理、临床意义和心脏手术中右心衰的处理。

关键词：右心室功能心脏手术病理生理功能评估围手术期解剖心血管疾病右心功能障碍

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究

引用

英国医学杂志中文版 2006年第5期9卷 282-285页

作者： Alexander T Cohen Bruce L Davidson Alexander S Gallus Michael R Lassen Martin H Prins Witold Tomkowski Alexander G G Turpie Jan F M Egberts Anthonie W A Lensing 石汉平（译）王深明（校） Department of Surety Guy＇s King＇s and St Thomas＇s School of Medicine London SE5 9PJ Pulmonary and Critical Care University of Washington School of Medicine and Swedish Medical Center Seattle WA USA Department of Haematology Flinders Medical Centre Adelaide SA Australia Spine clinic Department of Clinical Research Horsholm Denmark Department of clinical Epidemiology and Technology Assessment Academic Hospital Maastricht Netherlands Intensive Care National TB and Lung Diseases Research Institute Warsaw Poland Department of Medicine Hamilton Health Sciences Hamilton ONCanada clinical Development NV Organon Oss Netherlands Center for Vascular Medicine Academic Medical Center Amsterdam Netherlands 不详

目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并... 详细信息

目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并急性呼吸系统疾患、急性炎症性或感染性疾病,预期至少住院4天以上。干预:2.5 mg Fondaparinux 或安慰剂,每天1次皮下注射,持续6～14天。观察指标:主要指标为静脉血栓形成(治疗后15天内采用双侧静脉造影检查)及有症状的静脉血栓;次要指标为死亡与出血。患者随访时间为1个月。结果:Fondaparinux 治疗组425例患者和安慰剂组414例患者接受了安全性分析(10例未治疗)。644例患者(75.9%)可接受主要指标分析。静脉血栓检出率在 Fondaparinux 治疗组为5.6%(18/321),安慰剂组为10.5%(34/323),相对危险减少46.7%(95% CI 7.7%～69.3%)。安慰剂组5例患者发生有症状的静脉血栓,Fondaparinux治疗组无患者发生有症状的静脉血栓(P=0.029)。两组均有1例(0.2%)患者发生严重出血。随访结束时,安慰剂组、Fondaparinux 治疗组分别死亡25(6.0%)、14(3.3%)例患者。结论:Fondaparinux 可有效预防急性内科老年患者无症状性及有症状的静脉血栓。严重出血几率两组相似。

关键词：安慰剂血栓静脉造影空白剂血管造影静脉血栓形成内科患者 Fondaparinux 对照研究老年

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

引用

World Journal of Gastroenterology 2016年第12期22卷 3418-3431页

作者： Ira Jacobson Stefan Zeuzem Robert Flisiak Brygida Knysz Stefan Lueth Dorota Zarebska-Michaluk Ewa Janczewska Peter Ferenci Moises Diago Anna Linda Zignego Rifaat Safadi Yaacov Baruch Dzhamal Abdurakhmanov Stephen Shafran Dominique Thabut Rafael Bruck Adrian Gadano Alexander James Thompson Justin Kopit Fiona Mc Phee Tracy Michener Eric A Hughes Philip D Yin Stephanie Noviello Weill Cornell Medical College New YorkNY 10029United States Icahn School of Medicine at Mount Sinai New YorkNY 10029United States JW Goethe University Hospital 60323 FrankfurtGermany Uniwersytet Medyczny w Bialymstoku 15-089 BialystokPoland EMC and Medical University 50-220 WroclawPoland Universitatsklinikum Hamburg-Eppendorf 20246 HamburgGermany Wojewodzki Szpital Zespolony w Kielcach 25-736 KielcePoland ID clinic 41-400 MyslowicePoland Medizinische Universitat Wien 1090 ViennaAustria clinica Quiron 46010 ValenciaSpain Universita degli Studi di Firenze 50121 FlorenceItaly Holy Family Hospital Nazareth 6004Israel Rambam Medical Center Haifa 31096Israel 1st Moscow State Medical University N.A.I.M.Sechenov 119991 MoscowRussia University of Alberta Hospital EdmontonAlberta T6G 2B7Canada Groupe Hospitalier Pitie-Salpetriere 75013 ParisFrance Tel Aviv Sourasky Medical Center and Tel Aviv University Tel Aviv 64239Israel Hospital Italiano de Buenos Aires Buenos Aires C1181ACHArgentina St.Vincents Hospital and the University of Melbourne Melbourne 3065Australia Fiona McPhee Bristol-Myers Squibb Research and DevelopmentWallingfordCT 06492United States Bristol-Myers Squibb Research and Development PrincetonNJ 08450United States

AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin(peg IFN/RBV), in treatment-naive hepatitis C virus(HCV) genotype(GT) 1-infected ***: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned(2:1) to daclatasvir vs telaprevir, stratified by IL28 B rs12979860 host genotype(CC vs non-CC), cirrhosis status(compensated cirrhosis vs no cirrhosis), and HCV GT1 subtype(GT1a vs GT1b). Patients were selected by study inclusion criteria from a total of 793 enrolled patients. Patients received daclatasvir 60 mg once daily or telaprevir 750 mg 3 times daily plus peg IFN/RBV. Daclatasvir recipients received 24 wk of daclatasvir plus peg IFN/RBV; those without an extended rapid virologic response(e RVR; undetectable HCV-RNA at weeks 4 and 12) received an additional 24 wk of peg IFN/RBV. Telaprevir-treated patients received 12 wk of telaprevir plus peg IFN/RBV followed by 12(with e RVR) or 36(no e RVR) wk of peg IFN/RBV. The primary objective was to compare for noninferiority of sustained virologic response rates at posttreatment week 12(SVR12) in GT1b-infected patients. Key secondary objectives were to demonstrate that the rates of anemia(hemoglobin failure or relapse and HCV-RNA ≥ 1000 IU/m L, to investigate any link between NS5 A polymorphisms associated with daclatasvir resistance and virologic outcome. RESULTS: Patient demographics and disease characteristics were generally balanced across treatment arms; however, there was a higher proportion of black/African Americans in the daclatasvir groups(6.0% and 8.2% in the GT1 b and GT1 a groups, respectively) than in the telaprevi

关键词： Direct-acting antiviral Chronic hepatitis C Daclatasvir Genotype 1b NS5A inhibitor Liver disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism

引用

World Journal of Nephrology 2016年第5期5卷 437-447页

作者： Cláudia Ribeiro Maria Goretti Moreira Guimaraes Penido Milena Maria Moreira Guimaraes Marcelo de Sousa Tavares Bruno das Neves Souza Anderson Ferreira Leite Leonardo Martins Caldeira de Deus Lucas Joséde Campos Machado Center of Nephrology Santa Casa de Belo Horizonte HospitalBelo Horizonte CEP 30150320Minas GeraisBrazil Pediatric Nephrology Unit School of MedicineFederal University of Minas GeraisBelo Horizonte CEP 30130100Minas GeraisBrazil Pediatric Nephrology Unit Center of NephrologySanta Casa de Belo Horizonte HospitalBelo Horizonte CEP 30150320Minas GeraisBrazil Department of Internal Medicine School of Medic Federal University of Minas GeraisBelo Horizonte C30130100Minas GeraisBrazil School of Medicine Federal University of Minas GeraisBelo Horizonte CEP 30130100Minas GeraisBrazil Department of Cardiology Clinic HospitalFederal University of Minas GeraisBelo Horizonte CEP 30130100Minas GeraisBrazil

AIM To evaluate the parathyroid ultrasonography and define parameters that can predict poor response to treatment in patients with secondary hyperparathyroidism due to renal *** This cohort study evaluated 85 patients with chronic kidney disease stage V with parathyroid hormone levels above 800 pg/mL. All patients underwent ultrasonography of the parathyroids and the following parameters were analyzed: Demographic characteristics(etiology of chronic kidney disease, gender, age, dialysis vintage, vascular access, use of vitamin D), laboratory(calcium, phosphorus, parathyroid hormone, alkaline phosphatase, bone alkaline phosphatase), and the occurrence of bone changes, cardiovascular events and death. The χ~2 test were used to compare proportions or the Fisher exact test for small sample frequencies. Student t-test was used to detect differences between the two groups regarding continuous *** Fifty-three patients(66.4%) had parathyroid nodules with higher levels of parathyroid hormone, calcium and phosphorus. Sixteen patients underwent parathyroidectomy and had higher levels of phosphorus and calcium × phosphorus product(P = 0.03 and P = 0.006, respectively). They also had lower mortality(32% vs 68%, P = 0.01) and lower incidence of cardiovascular or cerebrovascular events(27% vs 73%, P = 0.02). Calcium × phosphorus product above 55 mg^2/dL^2 [RR 1.48(1.06, 2.08), P = 0.03], presence of vascular calcification [1.33(1.01, 1.76), P = 0.015] and previous occurrence of vascular events [RR 2.25(1.27, 3.98), P failure.

关键词： Secondary hyperparathyroidism Parathyroid ultrasonography Calcium Phosphorus Parathyroid hormone Alkaline phosphatase Chronic kidney disease Bone alkaline phosphatase

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：